Use of omeprazole as a probe drug for CYP2C19 phenotype in swedish caucasians: Comparison with S-mephenytoin hydroxylation phenotype and CYP2C19 genotype

Pharmacogenetics

Volumn 5, Issue 6, 1995, Pages 358-363

  Chang, Ming ^a   Dahl, Marja Liisa ^a   Tybring, Gunnel ^a   Götharson, Eva ^a   Bertilsson, Leif ^a  

^a KAROLINSKA UNIVERSITY HOSPITAL   (Sweden)

Author keywords

CYP2C19; Genotype; Mephenytoin; Omeprazole; Phenotype

Indexed keywords

CYTOCHROME P450 ISOENZYME; DRUG METABOLITE; HYDROXYOMEPRAZOLE; MEPHENYTOIN; OMEPRAZOLE; UNCLASSIFIED DRUG;

ADULT; ALLELE; ARTICLE; CAUCASIAN; CLINICAL TRIAL; CONTROLLED CLINICAL TRIAL; CONTROLLED STUDY; DRUG BLOOD LEVEL; DRUG METABOLISM; FEMALE; GENE AMPLIFICATION; GENE MUTATION; GENETIC POLYMORPHISM; GENOTYPE; HETEROZYGOSITY; HOMOZYGOSITY; HUMAN; HYDROXYLATION; MALE; NORMAL HUMAN; ORAL DRUG ADMINISTRATION; PHENOTYPE; POLYMERASE CHAIN REACTION; PRIORITY JOURNAL; RANDOMIZED CONTROLLED TRIAL; SWEDEN; VOLUNTEER;

2-PYRIDINYLMETHYLSULFINYLBENZIMIDAZOLES; ADULT; ALLELES; ARYL HYDROCARBON HYDROXYLASES; CYTOCHROME P-450 ENZYME SYSTEM; EUROPEAN CONTINENTAL ANCESTRY GROUP; FEMALE; GENOTYPE; HUMANS; HYDROXYLATION; MALE; MEPHENYTOIN; MIDDLE AGED; MIXED FUNCTION OXYGENASES; MOLECULAR PROBES; OMEPRAZOLE; PHARMACOGENETICS; PHENOTYPE; SWEDEN;

EID: 0029587180     PISSN: 0960314X     EISSN: None     Source Type: Journal    
DOI: 10.1097/00008571-199512000-00004     Document Type: Article

References (27)

1. Andersson T, Regârdh CG, Lou YC, Zhang Y, Dahl ML, Bertilsson L. Polymorphic hydroxylation of S-mephenytoin and omeprazole metabolism in Caucasian and Chinese subjects. Pharmacogenetics 1992: 2, 32-37.
2. Andersson T, Miners JO, Veronese M, Tassaneeyakul W, Tassa-neeyakul W, Meyer UA, Birkett DJ. Identification of human liver cytochrome P450 isoforms mediating omeprazole metabolism. Br J Clin Pharmacol 1993: 36, 521-531.
3. Bertilsson L, Kalow W. Why are diazepam metabolism and polymorphic S-mephenytoin hydroxylation associated with each other in white and Korean populations but not in Chinese populations? Clin Pharmacol Ther 1993: 53, 608-610.
4. Bertilsson L, Dahl ML, Sjöqvist F, Àberg-Wistedt A, Humble M, Johansson I, Lundquist E, Ingelman-Sundberg M. Molecular basis for rational megaprescribing in ultrarapid hydroxylators of debrisoquine. Lancet 1993: 341, 63.
5. Bertilsson L, Lou Y-Q, Du Y-L, Liu Y, Kuang T-Y, Liao X-M, Wang K-Y, Reviriego J, Iselius L, Sjöqvist F. Pronounced differences between native Chinese and Swedish populations in the polymorphic hydroxylations of debrisoquin and S-mephenytoin. Clin Pharmacol Ther 1992: 51, 388-397.
6. Chang M, Tybring G, Dahl ML, Götharson E, Sagar M, Seensalu R, Bertilsson L. Interphenotype differences in disposition and effect on gastrin levels of omeprazole - suitability of omeprazole as a probe for CYP2C19. Br J Clin Pharmacol 1995: 39, 511-518.
7. Dahl ML, Johansson I, Bertilsson L, Ingelman-Sundberg M, Sjöqvist F. Ultrarapid hydroxylation of debrisoquine in a Swedish population - analysis of the molecular genetic basis. J Pharmacol Exp Ther 1995: 274, 516-520.
8. de Morais SM, Wilkinson GR, Blaisdell J, Nakamura K, Meyer UA, Goldstein JA. The major genetic defect responsible for the polymorphism of S-mephenytoin metabolism in humans. J Biol Chem 1994a: 269,15419-15422.
9. de Morais SM, Wilkinson GR, Blaisdell J, Meyer UA, Nakamura K, Goldstein JA. Identification of a new genetic defect responsible for the polymorphism of (S)-mephenytoin metabolism in Japanese. Molec Pharmacol 1994b: 46, 594-598.
10. Goldstein JA, de Morais SMF. Biochemistry and molecular biology of the human CYP2C subfamily. Pharmacogenetics 1994: 4, 285-299.
11. Goldstein JA, Faletto MB, Romkes-Sparks M, Sallivan T, Kitareewan S, Raucy JL, Lasker JM, Ghanayem BI. Evidence that CYP2C19 is the major S-mephenytoin 4’-hydroxylase in humans. Biochemistry 1994: 33,1743-1752.
12. Horai S, Hayasaka K, Kondo R, Tsugane K, Takahata N. Recent African origin of modern humans revealed by complete sequences of homoid mitochondrial DNAs. Proc Natl Acad Sci USA 1995: 92,532-536.
13. Inaba T, Jurima M, Kalow W. Family studies of mephenytoin hydroxylation deficiency. Am J Hum Genet 1986: 38, 768-772.
14. Johansson I, Lundqvist E, Bertilsson L, Dahl ML, Sjöqvist F, Ingelman-Sundberg M. Inherited amplification of an active gene in the cytochrome P450 CYP2D locus as a cause of ultrarapid metabolism of debrisoquine. Proc Natl Acad Sci USA 1993: 90, 11825-11829.
15. Kupfer A, Preisig R. Pharmacogenetics of mephenytoin: a new drug hydroxylation polymorphism in man. Eur J Clin Pharmacol 1984: 26, 753-759.
16. Lagerström PO, Persson BA. Determination of omeprazole and metabolites in plasma and urine by liquid chromatography. J Chromatogr 1984: 309, 347-356.
17. Masimirembwa C, Bertilsson L, Johansson I, Hasler JA, Ingelman-Sundberg M. Phenotyping and genotyping of S-mephenytoin hydroxylase (cytochrome P450 2C19) in a Shona population in Zimbabwe. Clin Pharmacol Ther 1995: 57, 656-661.
18. Nakamura K, Goto F, Ray WA, McAllister CB, Jacqz E, Wilkinson GR, Branch RA. Interethnic differences in genetic polymer phism of debrisoquin and mephenytoin hydroxylation between Japanese and Caucasian population. Clin Pharmacol Ther 1985: 38. 402-408.
19. Relling MV, Ayers D, Heideman RL. Mephenytoin phenotyping: lack of haematological effect and timing of urine collections. Pharmacogenetics 1991: 1, 42-49.
20. Sanz EJ, Villen T, Alm C, Bertilsson L. S-Mephenytoin hydroxylation phenotypes in a Swedish population determined after coad-minstration with debrisoquin. Clin Pharmacol Ther 1989: 45, 495-499.
21. Sohn DR. Kobayashi K, Chiba K, Lee KH, Shin SG, Ishizaki T. Disposition kinetics and metabolism of omeprazole in extensive and poor metabolizers of S-mephenytoin 4’-hydroxylation recruited from an Oriental population. J Pharmacol Exp Ther 1992: 262,1195-1202.
22. Tybring G, Bertilsson L. A methodological investigation on the estimation of the S-mephenytoin hydroxylation phenotype using the urinary S/R ratio. Pharmacogenetics 1992: 2, 241-243.
23. Walan A. Clinical experience with omeprazole assessment of efficacy and safety. Gastroenterol Hepatol 1989: 4 (suppl 2): 27-33.
24. Ward SA, Goto F, Nakamura K, Jacqz E, Wilkinson GR, Branch RA. S-mephenytoin 4-hydroxylase is inherited as an autosomal-recessive trait in Japanese families. Clin Pharmacol Ther 1987: 42, 96-99.
25. Ward SA, Helsby NA, Skjelbo E, Brosen K, Gram LF, Breckenridge AM. The activation of the biguanide antimalarial proguanil co-segregates with the mephenytoin oxidation polymor-phism-a panel study. Br J Clin Pharmacol 1991: 31, 689-692.
26. Wilkinson GR, Guengerich FP, Branch RA. Genetic polymorphism of S-mephenytoin hydroxylation. In: Kalow W, ed. Pharmacogenetics of drug metabolism. New York: Pergamon Press, 1992: 657-685.
27. Wrighton SA, Stevens JC, Becker GW, VandenBranden M. Isolation and characterization of human liver cytochrome P450 2C19: correlation between 2C19 and S-mephenytoin 4’-hydroxyl-ation. Arch Biochem Biophys 1993: 306, 240-245.